Share
Title
Patient-reported outcomes after 12 months of maintenance therapy with cabotegravir + rilpivirine long-acting compared with bictegravir/emtricitabine/tenofovir alafenamide in the Phase 3b SOLAR study
Presenter
Jenny Scherzer
Authors
V. Chounta1, C. Mussini2, C. Cazanave3, E. Adachi4, B. Eu5, M. Montero Alonso6, G. Crofoot7, K. Sutton8, D. Sutherland-Phillips8, R. Urbaityte9, A. Ehmann10, J. Scherzer11, P. de los Rios8, R. D'Amico8, W.R. Spreen8
Institutions
1ViiV Healthcare, Brentford, United Kingdom, 2University of Modena and Reggio Emilia, Modena, Italy, 3Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France, 4The University of Tokyo, Tokyo, Japan, 5Prahran Market Clinic, Melbourne, Australia, 6Hospital Universitario y Politécnico La Fe, Valencia, Spain, 7The Crofoot Research Center, Houston, United States, 8ViiV Healthcare, Durham, United States, 9GSK, London, United Kingdom, 10GSK, Ballston Spa, United States, 11ViiV Healthcare, Munich, Germany

BACKGROUND: The SOLAR (NCT04542070) Phase 3b study demonstrated noninferior virologic efficacy of switching to cabotegravir+rilpivirine long-acting (CAB+RPV LA) dosed Q2M from daily oral bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) vs. continuing BIC/FTC/TAF over 12 months in suppressed ART-experienced people living with HIV-1. Patient-reported outcomes (PROs) from SOLAR are presented herein.
METHODS: PRO endpoints included a treatment preference questionnaire; overall treatment satisfaction and satisfaction with treatment flexibility, convenience, and willingness to continue treatment (HIV Treatment Satisfaction Questionnaire status version [HIVTSQs]); acceptability of injections (Perception of Injection questionnaire); and three single-item questions exploring an individual’s fear of disclosure, anxiety relating to adherence requirements, and daily reminder of their HIV status (FAD questions).
RESULTS: Of 670 participants, 447 (67%) switched to LA therapy and 223 (33%) continued BIC/FTC/TAF (2:1 randomization). After 12 months of treatment (or at withdrawal), most (90%) questionnaire respondents preferred LA injectable treatment vs. daily oral therapy (5%); the remaining 5% reported no preference. The top reason for preferring LA therapy was not having to worry about taking HIV medicine (85%). A statistically significant increase from baseline favoring CAB+RPV LA vs. BIC/FTC/TAF was reported in overall treatment satisfaction, and satisfaction with treatment flexibility, treatment convenience, and willingness to continue treatment after 12 months of therapy (Table). Acceptability of injections improved after 12 months of treatment. At baseline (prior to randomized treatment), 49% (n=218/447) of participants in the CAB+RPV LA arm and 43% (n=97/223) in the BIC/FTC/TAF arm reported "always"/"often" to at least one FAD question. After 12 months of therapy, a higher proportion of respondents in the CAB+RPV LA group reported improvements in all three FAD questions compared with respondents receiving BIC/FTC/TAF.


CONCLUSIONS: Switching to CAB+RPV LA Q2M was associated with improved treatment satisfaction, preferred by 90% of participants, while also providing emotional well-being benefits including relief from the fear of disclosure and anxiety surrounding adherence.

Download the e-Poster (PDF)

Download the e-Poster (Movie)